Cipla says DRI searched Mumbai office and Bhiwandi depot
In short
Cipla said the DRI searched its Vikhroli office and Bhiwandi depot on November 16. The search was linked to the classification and tax exemption of an imported pharmaceutical finished product.
Cipla said the matter did not have any material impact on its finances or operations. Investors will watch for any further regulatory action.
What the reporting says
Cipla disclosed that the Directorate of Revenue Intelligence conducted searches at its Vikhroli office and Bhiwandi depot on November 16 over the classification and exemption of an imported pharmaceutical finished product. The company said there was no material impact on its financials or operations. The disclosure puts attention on an import-related compliance matter at the drugmaker.
Why it matters
Cipla disclosed that the DRI searched its Vikhroli office and Bhiwandi depot on November 16 in connection with the classification and exemption of an imported pharmaceutical finished product. The company said there was no material impact on its financials or operations. The event matters for Cipla because it raises a regulatory and compliance issue tied to an imported drug product, even as the company reported no business disruption.